American Oriental Bioengineering Inc
American Oriental Bioengineering, Inc. engages in the development, manufacture, and commercialization of various pharmaceutical and healthcare products. The company primarily provides prescription pharmaceutical products, including Shuanghuanglian Lyophilized Injection Powder under the SHL brand for the treatment of flu symptoms, such as high fever, cough, and sore throat, as well as upper respir… Read more
American Oriental Bioengineering Inc (AOBI) - Total Assets
Latest total assets as of September 2013: $427.62 Million USD
Based on the latest financial reports, American Oriental Bioengineering Inc (AOBI) holds total assets worth $427.62 Million USD as of September 2013.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
American Oriental Bioengineering Inc - Total Assets Trend (2000–2012)
This chart illustrates how American Oriental Bioengineering Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
American Oriental Bioengineering Inc - Asset Composition Analysis
Current Asset Composition (December 2012)
American Oriental Bioengineering Inc's total assets of $427.62 Million consist of 21.4% current assets and 78.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 1.6% |
| Accounts Receivable | $50.23 Million | 11.3% |
| Inventory | $20.57 Million | 4.6% |
| Property, Plant & Equipment | $171.38 Million | 38.4% |
| Intangible Assets | $175.87 Million | 39.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2000–2012)
This chart illustrates how American Oriental Bioengineering Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: American Oriental Bioengineering Inc's current assets represent 21.4% of total assets in 2012, a decrease from 58.3% in 2000.
- Cash Position: Cash and equivalents constituted 1.6% of total assets in 2012, down from 16.7% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 39.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is intangible assets at 39.4% of total assets.
American Oriental Bioengineering Inc Competitors by Total Assets
Key competitors of American Oriental Bioengineering Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
American Oriental Bioengineering Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - American Oriental Bioengineering Inc generates 0.33x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - American Oriental Bioengineering Inc is currently not profitable relative to its asset base.
American Oriental Bioengineering Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.51 | 1.01 | 2.88 |
| Quick Ratio | 0.35 | 0.79 | 2.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-61.54 Million | $ 869.37K | $ 86.42 Million |
American Oriental Bioengineering Inc - Advanced Valuation Insights
This section examines the relationship between American Oriental Bioengineering Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.00 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -21.0% |
| Total Assets | $446.31 Million |
| Market Capitalization | $4.65 USD |
Valuation Analysis
Below Book Valuation: The market values American Oriental Bioengineering Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: American Oriental Bioengineering Inc's assets decreased by 21.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for American Oriental Bioengineering Inc (2000–2012)
The table below shows the annual total assets of American Oriental Bioengineering Inc from 2000 to 2012.
| Year | Total Assets | Change |
|---|---|---|
| 2012-12-31 | $446.31 Million | -21.00% |
| 2011-12-31 | $564.98 Million | -7.61% |
| 2010-12-31 | $611.54 Million | +6.08% |
| 2009-12-31 | $576.48 Million | +10.00% |
| 2008-12-31 | $524.05 Million | +48.16% |
| 2007-12-31 | $353.71 Million | +90.91% |
| 2006-12-31 | $185.27 Million | +86.35% |
| 2005-12-31 | $99.42 Million | +132.10% |
| 2004-12-31 | $42.84 Million | +97.65% |
| 2003-12-31 | $21.67 Million | +99.78% |
| 2002-12-31 | $10.85 Million | +2642.39% |
| 2001-12-31 | $395.57K | +531.61% |
| 2000-12-31 | $62.63K | -- |